The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).
 
Connie Lee Batlevi
No Relationships to Disclose
 
Paul A. Hamlin
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Juno Therapeutics
Research Funding - Incyte; Molecular Templates; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Matthew J. Matasar
Honoraria - Roche; Spectrum Pharmaceuticals
Research Funding - GlaxoSmithKline; Roche; Spectrum Pharmaceuticals
 
Steven M. Horwitz
Consulting or Advisory Role - Celgene; Forty Seven; HUYA Bioscience International; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Millennium; Seagen
Research Funding - ADC Therapeutics; Aileron Therapeutics; Celgene; Forty Seven; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Seagen; Spectrum Pharmaceuticals; Takeda
 
John F. Gerecitano
Honoraria - Abbvie; Bayer; Genentech/Roche; Gilead Sciences; Samus Therapeutics
Consulting or Advisory Role - Abbvie; Bayer; Genentech/Roche; Gilead Sciences; Samus Therapeutics
 
Craig H. Moskowitz
Consulting or Advisory Role - Celgene; Genentech; Merck; Seagen
Research Funding - Merck; Pharmacyclics; Seagen
 
David J. Straus
No Relationships to Disclose
 
Andrew David Zelenetz
Stock and Other Ownership Interests - Adaptive Biotechnologies
Honoraria - Kirin Pharmaceuticals; Medscape; Takeda
Consulting or Advisory Role - Acerta Pharma; Alissa Pharma; Alphasights; Amgen; Celgene; Genentech/Roche; Gilead Sciences; Hospira; Pharmacyclics
Research Funding - BeiGene; Bristol-Myers Squibb; Genentech/Roche; Gilead Sciences; MEI Pharma
Travel, Accommodations, Expenses - Gilead Sciences; Kirin Pharmaceuticals; Medscape; Takeda
Other Relationship - Boehringer Ingelheim; Quintiles
 
Pamela Drullinsky
No Relationships to Disclose
 
Amanda Copeland
Honoraria - Seagen; Teva
Consulting or Advisory Role - Seagen; Teva
 
Salma Ahsanuddin
No Relationships to Disclose
 
Devin Callan
No Relationships to Disclose
 
Benjamin Freidin
No Relationships to Disclose
 
Robert Porzio
No Relationships to Disclose
 
Thu Oanh Dang
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Jurgen Rademaker
No Relationships to Disclose
 
Heiko Schöder
No Relationships to Disclose
 
Ahmet Dogan
Consulting or Advisory Role - Novartis; Seagen
 
Anas Younes
Honoraria - Abbvie; Bristol-Myers Squibb; Gilead Sciences; Janssen; Merck; Roche; Takeda
Consulting or Advisory Role - Asana Biosciences; Bristol-Myers Squibb; Gilead Sciences; Janssen; Merck; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Constillation (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst)